Zheng Quan Zhi Xing·2025-07-24 16:33Core Viewpoint - The legal opinion issued by Beijing Wan Shang Tian Qin Law Firm confirms that the differentiated dividend distribution plan of Beijing Chunli Zhengda Medical Device Co., Ltd. complies with relevant laws and regulations, ensuring no harm to the interests of the company and its shareholders [4][10]. Group 1: Differentiated Dividend Distribution - The differentiated dividend distribution is based on the company's 2024 profit distribution plan, which proposes a cash dividend of 0.49 RMB per 10 shares, with no stock dividends or capital reserve transfers [6][8]. - The total number of shares participating in the distribution is 382,191,649, which includes 287,051,149 A shares and 95,140,500 H shares, after excluding the repurchased shares [8][9]. - The company has repurchased 1,376,851 A shares, accounting for approximately 0.4774% of the total A shares, which do not participate in the dividend distribution [6][8]. Group 2: Legal Compliance and Verification - The law firm conducted thorough verification of the documents and materials provided by the company, ensuring their authenticity and completeness [2][3]. - The legal opinion is strictly based on Chinese laws and regulations, and does not cover any non-legal professional matters such as accounting or finance [3][4]. - The law firm confirms that the differentiated dividend distribution aligns with the provisions of the Company Law, Securities Law, and relevant regulatory guidelines [4][10]. Group 3: Impact on Stock Price - The differentiated dividend distribution is expected to have a minimal impact on the A-share ex-dividend reference price, with the absolute value of the impact being less than 1% [10]. - The calculated A-share ex-dividend reference price is approximately 18.7212 RMB per share, based on the last closing price and the cash dividend [9][10].